A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses

Documenti analoghi

• Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2000)
• Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes
  di: Faber-Elmann, Anat, et al.
  Pubblicazione: (1998)
• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4(+) T cells
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2003)
• Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.
  di: Katz-Levy, Y, et al.
  Pubblicazione: (1993)
• Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.
  di: Zisman, E, et al.
  Pubblicazione: (1996)